APONTIS PHARMA AG · ISIN: DE000A3CMGM5 · EQS - Company News

APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted

APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted Revenue growth for Single Pill combinations in 9M 2024 to EUR 26.2 million (9M 2023: EUR 17.9 million) Novartis collaboration (asthma products) contributes EUR 5.6 million to revenues EBITDA rises to EUR 2.7 million (9M 2023: EUR -7.0 million) on the back of higher revenues and a reduced cost base Net result profitable at EUR 0.8 million (9M 2023: net loss of EUR 6.2 million) ...

XETR:APPH Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News APONTIS PHARMA AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (2)
Directors Dealings (10)
Short Selling (DE) (0)
Short Selling (UK) (0)
07 November 2024 07:30AM
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
DE000A3CMGM5
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted Revenue growth for Single Pill combinations in 9M 2024 to EUR 26.2 million (9M 2023: EUR 17.9 million) Novartis collaboration (asthma products) contributes EUR 5.6 million to revenues EBITDA rises to EUR 2.7 million (9M 2023: EUR ...
APONTIS PHARMA AG
About the publication
30 October 2024 04:20PM
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
DE000A3CMGM5
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer   Joint reasoned statement by Management Board and Supervisory Board published Offer price of EUR 10.00 per share represents an attractive premium of around 52.9% compared to the closing price on 15 October 2024 and a premium of 38.3% com...
APONTIS PHARMA AG
About the publication
16 October 2024 11:55AM
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer
DE000A3CMGM5
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer   APONTIS PHARMA and Zentiva signed an investment agreement today Growth strategy of APONTIS PHARMA to be continued together with Zentiva APONTIS PHARMA to benefit from the European footprint, the existing research and ...
APONTIS PHARMA AG
About the publication
16 October 2024 11:50AM
APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer Monheim / Rhein, 16 October 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5), Zentiva Pharma GmbH...
APONTIS PHARMA AG
About the publication
09 August 2024 07:30AM
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
DE000A3CMGM5
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed   Revenue growth for Single Pill combinations in the first half of 2024 to EUR 17.9 million (H1 2023: EUR 12.1 million), also due to a competitor’s temporary inability to deliver in first quarter of 2024 New ...
APONTIS PHARMA AG
About the publication
27 June 2024 07:30AM
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
DE000A3CMGM5
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill combinations in the German market, expands its Executive Board with a view t...
APONTIS PHARMA AG
About the publication
27 June 2024 07:30AM
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
DE000A3CMGM5
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill combinations in the German market, expands its Executive Board with a view t...
APONTIS PHARMA AG
About the publication
04 June 2024 07:30AM
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
DE000A3CMGM5
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management   Mila Brückel appointed as Head of Supply Chain Extensive expertise in managing global supply chain programs from positions at Merck Healthcare Monheim / Rhein, 4 June 2024. APONTIS PHARMA AG (Ticker APPH ...
APONTIS PHARMA AG
About the publication
08 May 2024 07:30AM
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
DE000A3CMGM5
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed   Growth in revenue of Single Pill combinations to EUR 8.8 million in Q1 2024 (3M 2023: EUR 6.6 million), also due to a competitor’s temporary inability to supply products Cooperation busines...
APONTIS PHARMA AG
About the publication
05 April 2024 10:17AM
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
DE000A3CMGM5
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5) has entered into a five-year agreement with Novartis Pharma GmbH to take over the distribution and marketing of the patent-protected medi...
APONTIS PHARMA AG
About the publication
05 April 2024 10:10AM
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) ha...
APONTIS PHARMA AG
About the publication
28 March 2024 07:30AM
APONTIS PHARMA expects profitable growth again in 2024
DE000A3CMGM5
APONTIS PHARMA expects profitable growth again in 2024   Total sales 2023 of EUR 37.0 million exceed reduced forecast of EUR 36.1 million (2022: EUR 55.7 million) EBITDA 2023 at EUR -7.7 million before restructuring expenses (forecast: EUR -8.6 million before restructuring expenses) One-off restructuring expenses of EUR 5.6 million at the lower ...
APONTIS PHARMA AG
About the publication
28 March 2024 07:30AM
APONTIS PHARMA expects profitable growth again in 2024
DE000A3CMGM5
APONTIS PHARMA expects profitable growth again in 2024   Total sales 2023 of EUR 37.0 million exceed reduced forecast of EUR 36.1 million (2022: EUR 55.7 million) EBITDA 2023 at EUR -7.7 million before restructuring expenses (forecast: EUR -8.6 million before restructuring expenses) One-off restructuring expenses of EUR 5.6 million at the lower ...
APONTIS PHARMA AG
About the publication
06 February 2024 07:30AM
APONTIS PHARMA successfully completes performance and efficiency improvement program
DE000A3CMGM5
APONTIS PHARMA successfully completes performance and efficiency improvement program   New go-to-market approach comes into action earlier than planned on 1 March 2024 Headcount reduced from 185 to 110 employees Expenses at EUR 5.6 million at lower end of planning – no further burdens in financial year 2024 Savings – based on a full 12-month pe...
APONTIS PHARMA AG
About the publication
09 November 2023 07:30AM
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
DE000A3CMGM5
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published   Comprehensive program for achieving significant savings while increasing the effectiveness of sales and marketing presented Savings of EUR 6.0 million to EUR 7.0 million expected over a...
APONTIS PHARMA AG
About the publication
08 November 2023 08:00PM
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program Monheim am Rhein, 8 November 2023. APONTIS PHARMA AG („Company“, Ticker APPH / ISIN DE000A3CMGM5) today based on the nine-month figures of the current financial year ann...
APONTIS PHARMA AG
About the publication
10 August 2023 07:30AM
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline
DE000A3CMGM5
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline   Single Pill revenue of EUR 12.1 million (6M 2022: EUR 17.7 million) Atorimib down EUR 5.3 million due to ongoing supply bottlenecks – normalization as of November announced by supplier Strong growth of Tonotec HCT (+41%) and Tonotec Lipid (+88%), Biramlo, Losamlo...
APONTIS PHARMA AG
About the publication
31 July 2023 06:40PM
Co-promotion contract with AstraZeneca not to be continued in 2024
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024 Monheim am Rhein, 31 July 2023. APONTIS PHARMA AG („APONTIS PHARMA“ or the „Company“, Ticker APPH / ISIN DE000A3CMGM5) has been informed by AstraZeneca that the co-promotion ...
APONTIS PHARMA AG
About the publication
31 July 2023 06:40PM
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024 Monheim am Rhein, 31 July 2023. APONTIS PHARMA AG („APONTIS PHARMA“ or the „Company“, Ticker APPH / ISIN DE000A3CMGM5) has been informed by AstraZeneca that the co-promotion ...
APONTIS PHARMA AG
About the publication
27 July 2023 10:15PM
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched
DE000A3CMGM5
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched   Preliminary Single Pill revenue declines by 32% to EUR 12.1 million in first half of 2023 (H1 2022: EUR 17.7 million), mainly due to delivery delays Preliminary total reve...
APONTIS PHARMA AG
About the publication
27 July 2023 10:15PM
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched
DE000A3CMGM5
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched   Preliminary Single Pill revenue declines by 32% to EUR 12.1 million in first half of 2023 (H1 2022: EUR 17.7 million), mainly due to delivery delays Preliminary total reve...
APONTIS PHARMA AG
About the publication
27 July 2023 10:10PM
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 Monheim am Rhein, 27 July 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) has withdrawn today its forecast for fiscal year 2...
APONTIS PHARMA AG
About the publication
27 July 2023 10:10PM
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 Monheim am Rhein, 27 July 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) has withdrawn today its forecast for fiscal year 2...
APONTIS PHARMA AG
About the publication
10 July 2023 01:50PM
CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor
DE000A3CMGM5
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor Monheim, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, Karl-Heinz Gast, has informed the Supervisor...
APONTIS PHARMA AG
About the publication
10 July 2023 01:50PM
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor
DE000A3CMGM5
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor Monheim, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, Karl-Heinz Gast, has informed the Supervisor...
APONTIS PHARMA AG
About the publication
10 July 2023 01:45PM
CEO Karlheinz Gast resigns from office for personal reasons
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons Monheim am Rhein, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5), Karlheinz Gast, has infor...
APONTIS PHARMA AG
About the publication
10 July 2023 01:45PM
APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons Monheim am Rhein, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5), Karlheinz Gast, has infor...
APONTIS PHARMA AG
About the publication
29 June 2023 07:30AM
APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023
DE000A3CMGM5
APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023   Single Pill Finder online application shows real-time options to simplify therapy Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill New Single Pill Rosazimib on the mark...
APONTIS PHARMA AG
About the publication
29 June 2023 07:30AM
APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023
DE000A3CMGM5
APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023   Single Pill Finder online application shows real-time options to simplify therapy Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill New Single Pill Rosazimib on the mark...
APONTIS PHARMA AG
About the publication
09 May 2023 07:30AM
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition year in focusing on Single Pills
DE000A3CMGM5
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition year in focusing on Single Pills   Single Pill revenues in line with expectations, down 25% to EUR 6.6 million (3M 2022: EUR 8.7 million) Effects of tender for Atorimib partially offset by active sales measures, stronger sales development held back ...
APONTIS PHARMA AG
About the publication
09 May 2023 07:30AM
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition year in focusing on Single Pills
DE000A3CMGM5
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition year in focusing on Single Pills   Single Pill revenues in line with expectations, down 25% to EUR 6.6 million (3M 2022: EUR 8.7 million) Effects of tender for Atorimib partially offset by active sales measures, stronger sales development held back ...
APONTIS PHARMA AG
About the publication
08 May 2023 07:30AM
Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights
DE000A3CMGM5
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights   Market launch planned for 2027/2028 with medium-term sales potential of more than EUR 7.0 million p.a. in Germany alone 15 Single Pills announced for market...
APONTIS PHARMA AG
About the publication
08 May 2023 07:30AM
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights
DE000A3CMGM5
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights   Market launch planned for 2027/2028 with medium-term sales potential of more than EUR 7.0 million p.a. in Germany alone 15 Single Pills announced for market...
APONTIS PHARMA AG
About the publication
02 May 2023 09:50PM
APONTIS PHARMA AG adjusts forecast for fiscal year 2023
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG adjusts forecast for fiscal year 2023 Monheim am Rhein, 2 May 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) adjusts its guidance for fiscal year 2023 as a consequence of delivery difficulties at a...
APONTIS PHARMA AG
About the publication
02 May 2023 09:50PM
APONTIS PHARMA AG adjusts forecast for fiscal year 2023
DE000A3CMGM5
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG adjusts forecast for fiscal year 2023 Monheim am Rhein, 2 May 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) adjusts its guidance for fiscal year 2023 as a consequence of delivery difficulties at a...
APONTIS PHARMA AG
About the publication
27 April 2023 07:30AM
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024
DE000A3CMGM5
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024   New attractive therapy option for hypertension patients at high risk or with additional existing hyperlipidemia Medium-term annual sales potential of the new Sing...
APONTIS PHARMA AG
About the publication
27 April 2023 07:30AM
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024
DE000A3CMGM5
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024   New attractive therapy option for hypertension patients at high risk or with additional existing hyperlipidemia Medium-term annual sales potential of the new Sing...
APONTIS PHARMA AG
About the publication
12 April 2023 07:30AM
APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential
DE000A3CMGM5
APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential   New Single Pill with potential peak sales of more than EUR 6.0 million per year in Germany alone – market launch planned for the end of 2027 Currently five Single Pills with EU-wid...
APONTIS PHARMA AG
About the publication
12 April 2023 07:30AM
New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential
DE000A3CMGM5
APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential   New Single Pill with potential peak sales of more than EUR 6.0 million per year in Germany alone – market launch planned for the end of 2027 Currently five Single Pills with EU-wid...
APONTIS PHARMA AG
About the publication
09 March 2023 07:30AM
Revenue and EBITDA forecast slightly exceeded according to preliminary calculations
DE000A3CMGM5
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations   Single Pill revenues again grow at double-digit rate of 16% to EUR 36.5 million (2021: EUR 31.5 million) Single Pill revenues share rises to 66% (2021: 62%) Number of patients treated with Single Pills from AP...
APONTIS PHARMA AG
About the publication
09 March 2023 07:30AM
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations
DE000A3CMGM5
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations   Single Pill revenues again grow at double-digit rate of 16% to EUR 36.5 million (2021: EUR 31.5 million) Single Pill revenues share rises to 66% (2021: 62%) Number of patients treated with Single Pills from AP...
APONTIS PHARMA AG
About the publication
14 February 2023 07:30AM
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023
DE000A3CMGM5
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023   New Single Pill for the substitution treatment of hypertension, hypertension with coexisting coronary syndrome, and/or chronic heart failure Potential peak sales of the new Single Pill of around EUR 6 million Market launch in ...
APONTIS PHARMA AG
About the publication
14 February 2023 07:30AM
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023
DE000A3CMGM5
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023   New Single Pill for the substitution treatment of hypertension, hypertension with coexisting coronary syndrome, and/or chronic heart failure Potential peak sales of the new Single Pill of around EUR 6 million Market launch in ...
APONTIS PHARMA AG
About the publication
31 January 2023 07:30AM
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill
DE000A3CMGM5
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill   New Single Pill with potential peak sales of approx. EUR 1.3 million Market launch already planned for mid-2023 in Germany Number of announced market launches increases to eleven Single Pills Monheim am Rhein, 31 January 2023...
APONTIS PHARMA AG
About the publication
31 January 2023 07:30AM
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill
DE000A3CMGM5
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill   New Single Pill with potential peak sales of approx. EUR 1.3 million Market launch already planned for mid-2023 in Germany Number of announced market launches increases to eleven Single Pills Monheim am Rhein, 31 January 2023...
APONTIS PHARMA AG
About the publication
29 November 2022 07:30AM
Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
DE000A3CMGM5
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals   Continuous expansion of the Single Pill portfolio to meet the target of at least 20 Single Pills by 2026 – currently ten Single Pills in the portfolio Two new drugs with potential peak sales of EUR 4.0 million Market la...
APONTIS PHARMA AG
About the publication
29 November 2022 07:30AM
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
DE000A3CMGM5
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals   Continuous expansion of the Single Pill portfolio to meet the target of at least 20 Single Pills by 2026 – currently ten Single Pills in the portfolio Two new drugs with potential peak sales of EUR 4.0 million Market la...
APONTIS PHARMA AG
About the publication
10 November 2022 07:30AM
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets
DE000A3CMGM5
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets   Superiority of Single Pill therapy confirmed in the EU-funded prospective SECURE study and fully published in the prestigious New England Journal of Medicine Revenue from Single Pills +25.7% to EUR 27.3 million s...
APONTIS PHARMA AG
About the publication
More APONTIS PHARMA AG related information
Type Total Last Made by Go to
Corporate Research 2 16th August 2024 EQS Group AG Corporate Research
Directors Dealings 10 16th December 2024 be executive GmbH DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN